Friendship Biotech: Publication of Research Data on M701 Treatment for Malignant Ascites Stage II

Youtz Youshi Biotechnology announced that the development and clinical trial results of the dual-specificity antibody drug M701 targeting epithelial cell adhesion molecule and cluster of differentiation 3, independently developed by the company, for the treatment of malignant ascites caused by advanced epithelial tumors in China have been published in the internationally renowned medical journal "Experimental Hematology & Oncology". The Phase II study aimed to evaluate the efficacy and safety of M701 intraperitoneal infusion therapy in patients with moderate to large amounts of malignant ascites in advanced epithelial tumors. A total of 84 patients were included in the study, with 43 patients allocated to the M701 group receiving intraperitoneal puncture and intraperitoneal M701 infusion. The median survival time without puncture in the M701 group was 75 days, compared to 25 days in the control group.